Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 8Neoplasms 7Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Melanoma 3Skin Neoplasms 2Neoplastic Cells, Circulating 2Lung Diseases 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2von Hippel-Lindau Disease 1Weight Loss 1Uterine Cervical Neoplasms 1Sleep Apnea Syndromes 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Ovarian Insufficiency 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Overweight 1Obesity, Morbid 1Obesity 1Nervous System Diseases 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

cabozantinib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × High Grade Neuroendocrine Neoplasms × Blood Specimen Collection × Clear all
NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

Washington University School of Medicine

Phase 2 Active not recruiting
35 enrolled
Endocrine

High Grade Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡